Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

Chinese PLA General Hospital (301 Hospital)

Status: Completed

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Benign Prostatic Hypertrophy (BPH)

Treatments: Drug: 5-Alpha Reductase Inhibitors

Study type: Observational

Funder types: Other

Identifiers

NCT07196280

S2022-700-02

Details and patient eligibility

About

To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).

Enrollment: 10,000 estimated patients

Sex: Male

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients diagnosed with BPH or users of 5-ARIs

Exclusion criteria

• individuals who had cancer prior to the start of follow-up and those with pre-existing ASCVD